Alina Volkova

Dr. Alina Volkova


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YUYaroslav Ugolkov
Yaroslav Ugolkov
ANAntonina Nikitich
Antonina Nikitich
CLCristina Leon
Cristina Leon
GHGabriel Helmlinger
Gabriel Helmlinger
KPKirill Peskov
Kirill Peskov
AVAlina Volkova
Alina Volkova
The research & development (R&D) of novel therapeutic agents for the treatment of autoimmune diseases is challenged by highly complex pathogenesis and multiple etiologies of these conditions. The number of targeted therapies available on the market is limited, whereas the prevalence of autoimmune conditions in the global population continues to rise. Mathematical modeling of biological systems is an essential tool which may be applied in support of decision-making across R&D drug programs to improve the probability of success in the development of novel medicines. Over the past decades, multiple models of autoimmune diseases have been developed. Models differ in the spectra of quantitative data used in their development and mathematical methods, as well as in the level of “mechanistic granularity” chosen to describe the underlying biology. Yet, all models strive towards the same goal: to quantitatively describe various aspects of the immune response. The aim of this review was to conduct a systematic review and analysis of mathematical models of autoimmune diseases focused on the mechanistic description of the immune system, to consolidate existing quantitative knowledge on autoimmune processes, and to outline potential directions of interest for future model-based analyses. Following a systematic literature review, 38 models describing the onset, progression, and/or the effect of treatment in 13 systemic and organ-specific autoimmune conditions were identified, most models developed for inflammatory bowel disease, multiple sclerosis, and lupus (5 models each). ≥70% of the models were developed as nonlinear systems of ordinary differential equations, others – as partial differential equations, integro-differential equations, Boolean networks, or probabilistic models. Despite covering a relatively wide range of diseases, most models described the same components of the immune system, such as T-cell response, cytokine influence, or the involvement of macrophages in autoimmune processes. All models were thoroughly analyzed with an emphasis on assumptions, limitations, and their potential applications in the development of novel medicines.

20 December 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
YYYan‐Ou Yang
Yan‐Ou Yang
VSVictor Sokolov
Victor Sokolov
AVAlina Volkova
Alina Volkova
XLXing Liu
Xing Liu
Cristina LeonCristina Leon
Cristina Leon
XCXuejun Chen
Xuejun Chen
Axatilimab, a high‐affinity humanized immunoglobulin G4 monoclonal antibody against colony‐stimulating factor 1 receptor (CSF‐1R), is approved for the treatment of chronic graft‐versus‐host disease (cGVHD), and under investigation for idiopathic pulmonary fibrosis and solid tumors. The population pharmacokinetics (PK) and pharmacodynamics (PD) of axatilimab were characterized in healthy participants and patients with solid tumors or cGVHD using data from four clinical studies with 325 participants, including 278 patients with cGVHD. The model structure reflected the mechanism of action of axatilimab: blocking CSF‐1R signaling with axatilimab reduces the circulating levels of cells in the mononuclear phagocytic cell lineage (including nonclassical monocytic cells (NCMCs) and Kupffer cells), resulting in increases in circulating enzymes owing to reduced clearance by Kupffer cells. The structural model consisted of a two‐compartment axatilimab PK model and turnover PD models for CSF‐1, NCMCs, aspartate transaminase (AST), and creatine phosphokinase (CPK). Axatilimab PK and CSF‐1 equations also included saturable clearance components to reflect the competitive binding of axatilimab and CSF‐1 to CSF‐1R. Covariate search was conducted with the conditional sampling use for the stepwise approach based on correlation tests (COSSAC) approach. Covariate effects on model parameters, steady‐state axatilimab exposure, and NCMC concentrations were assessed. The final population PK/PD model was mathematically described with 6 ordinary differential equations and 39 model parameters. Among the 11 statistically significant covariates, one (body weight) and two (participant population type and baseline CPK) covariates affected axatilimab steady‐state exposure and steady‐state NCMC levels by > 20%, respectively. These results informed the axatilimab dosing strategy in patients with cGVHD.

13 May 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
AVAlina Volkova
Alina Volkova
VSVictor Sokolov
Victor Sokolov
FTFlorencia Tettamanti
Florencia Tettamanti
MVMeghna Verma
Meghna Verma
YUYaroslav Ugolkov
Yaroslav Ugolkov
HKHolly Kimko
Holly Kimko
Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).

8 January 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
AVAlina Volkova
Alina Volkova
BSBoris Shulgin
Boris Shulgin
GHGabriel Helmlinger
Gabriel Helmlinger
KPKirill Peskov
Kirill Peskov
VSVictor Sokolov
Victor Sokolov
Aims: To develop a model-informed methodology for the optimization of the Major Adverse Cardiac Events (MACE) composite endpoint, based on a model-based meta-analysis across anti-hypercholesterolemia trials of statin and anti-PCSK9 drugs.Methods and results: Mixed-effects meta-regression modeling of stand-alone MACE outcomes was performed, with therapy type, population demographics, baseline and change over time in lipid biomarkers as predictors. Randomized clinical trials up to June 28, 2022, of either statins or anti-PCSK9 therapies were identified through a systematic review process in PubMed and ClinicalTrials.gov databases. In total, 54 studies (270,471 patients) were collected, reporting 15 different single cardiovascular events. Treatment-mediated decrease in low density lipoprotein cholesterol, baseline levels of remnant and high-density lipoprotein cholesterol as well as non-lipid population characteristics and type of therapy were identified as significant covariates for 10 of the 15 outcomes. The required sample size per composite 3- and 4-point MACE endpoint was calculated based on the estimated treatment effects in a population and frequencies of the incorporated events in the control group, trial duration, and uncertainty in model parameters.Conclusion: A quantitative tool was developed and used to benchmark different compositions of 3- and 4-point MACE for statins and anti-PCSK9 therapies, based on the minimum population size required to achieve statistical significance in relative risk reduction, following meta-regression modeling of the single MACE components. The approach we developed may be applied towards the optimization of the design of future trials in dyslipidemia disorders as well as in other therapeutic areas.

19 June 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
YYYan‐Ou Yang
Yan‐Ou Yang
AVAlina Volkova
Alina Volkova
VSVictor Sokolov
Victor Sokolov
XLXing Liu
Xing Liu
Cristina LeonCristina Leon
Cristina Leon
XCXuejun Chen
Xuejun Chen
Axatilimab, a high‐affinity humanized monoclonal antibody that targets colony‐stimulating factor 1 receptor, is approved for the treatment of chronic graft‐versus‐host disease (cGVHD). Here, we describe the exposure‐response relationships for efficacy and safety in patients with cGVHD who received axatilimab. Exposure‐efficacy relationships were assessed in treated patients in the AGAVE‐201 study (n = 239); exposure‐safety relationships were assessed in treated patients in AGAVE‐201 (n = 239) and the phase 1/2 SNDX‐6352‐0503 study (n = 39). For binary or time‐to‐event endpoints, logistic or Cox regression analyses, respectively, were performed using axatilimab exposure metrics that were derived from a previously developed population pharmacokinetic/pharmacodynamic model. Overall response and ≥ 7‐point improvement in modified Lee Symptom Scale responses were associated with axatilimab exposure, with lower axatilimab exposure increasing the odds of a response. Duration of response was not associated with axatilimab exposure. Ten of 11 safety endpoints were associated with axatilimab exposure, with higher axatilimab exposure increasing the odds of adverse events. Among the 3 regimens evaluated in AGAVE‐201, the 0.3 mg/kg once every 2 weeks (Q2W) regimen had the highest predicted probability of response. Additionally, this dose group had the lowest predicted probability of event occurrence across all 10 safety endpoints associated with exposure among the evaluated regimens. Despite body weight influencing axatilimab exposure by > 20%, its effect on efficacy and safety endpoints remained minimal, with a maximum difference of ≤ 0.4% and ≤ 4.4% between the 1st and 4th quartiles of body weight, respectively. Taken together, these findings support the benefit–risk profile of axatilimab 0.3 mg/kg Q2W in patients with cGVHD.

23 November 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
VKVictoria Kulesh
Victoria Kulesh
IVIgor Vasyutin
Igor Vasyutin
AVAlina Volkova
Alina Volkova
KPKirill Peskov
Kirill Peskov
HKHolly Kimko
Holly Kimko
RARavindra Alluri
Ravindra Alluri
Assessment of drug‐induced effects on the cardiovascular (CV) system remains a critical component of the drug discovery process enabling refinement of the therapeutic index. Predicting potential drug‐related unintended CV effects in the preclinical stage is necessary for first‐in‐human dose selection and preclusion of adverse CV effects in the clinical stage. According to the current guidelines for small molecules, nonclinical CV safety assessment conducted via telemetry analyses should be included in the safety pharmacology core battery studies. However, the manual for quantitative evaluation of the CV safety signals in animals is available only for electrocardiogram parameters (i.e., QT interval assessment), not for hemodynamic parameters (i.e., heart rate, blood pressure, etc.). Various model‐based approaches, including empirical pharmacokinetic‐toxicodynamic analyses and systems pharmacology modeling could be used in the framework of telemetry data evaluation. In this tutorial, we provide a comprehensive workflow for the analysis of nonclinical CV safety on hemodynamic parameters with a sequential approach, highlight the challenges associated with the data, and propose respective solutions, complemented with a reproducible example. The work is aimed at helping researchers conduct model‐based analyses of the CV safety in animals with subsequent translation of the effect to humans seamlessly and efficiently.